In a recent abstract, Zhukouskaya et al. reported the development of hyperparathyroidism after three years of burosumab in children affected with X-linked hypophosphatemia whose baseline PTH levels were normal prior to therapy [7]. The gene discussed is PTH; the disease is hyperparathyroidism.